We identify the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism that is estimated to represent approximately 20% of overall cases, through a new type of risk assessment test for prospective mothers prior to (but not during) pregnancy, and for mothers during the early postnatal period. Our goal is to provide families with options to materially reduce the occurrence or severity of MARA. Our precision technology uses a blood test in women to identify the presence of a distinct cluster of autoantibodies that lead to MARA, thereby enabling the earliest risk assessment for the development of autism in a child.

Health Care

Life Sciences

MARAbio

Judy Van De Water

Michael S. Paul

The Clinical and Research Development team at MARAbio is dedicated to advancing the understanding and detection of Maternal Autoantibody Related Autism (MARA). This team focuses on developing and validating innovative assays to identify risk factors through blood tests, facilitating early risk assessment for prospective mothers. They collaborate with clinical experts and research institutions to enhance the efficacy and application of MARA risk assessment tools, ultimately aiming to empower families with actionable insights to reduce the prevalence and severity of this subtype of autism.

Clinical and Research Development

About

Team members

Other teams at MARAbio

Leadership Team